Publication | Closed Access

A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia

Hematological MalignancyOncologyGemtuzumab OzogamicinMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematologyPharmacotherapyPhase I/ii TrialPharmacologyMyeloid Neoplasia